Paradigm Biopharma - Durable responses observed for kOA
Paradigm has announced positive day-365 data from its Phase II trial (PARA_OA_008) assessing injectable pentosan polysulfate (iPPS) as a...
252 Views
Paradigm Biopharma - Progressing toward key near-term objectives
Paradigm has shared its June 2023 quarterly update. In Q423, net cash outflow from operating activities was A$17.1m (up from A$10.3m in Q323) or...
196 Views
Paradigm Biopharma - Pivotal Phase III progressing as planned
Paradigm has announced the completion of patient recruitment for stage one (dose selection) of its pivotal Phase III trial, PARA_OA_002, a...
337 Views
Paradigm Biopharma - Bolstering the iPPS data package for OA
Paradigm is focused on the development of injectable pentosan polysulfate (iPPS) for the treatment of osteoarthritis (OA). While the company has...
191 Views
Paradigm Biopharma - Active pipeline and catalysts ahead
Paradigm has shared its March 2023 quarterly update. In Q323, net cash outflow from operating activities was A$10.3m (A$28.1m for the first nine...
150 Views